Introduction
============

Information, entertainment, and advertisement consumption has been steadily moving away from print and network television stations to more specialized and targeted digital outlets, including Internet and mobile devices. By 2012, half of all mobile subscribers in the United States owned a smartphone \[[@ref1]\], jumping to nearly three-quarters within 3 years \[[@ref2]\]. In 2013, 57% of US smartphone owners reported receiving mobile ads at least once a day \[[@ref3]\]. Prescription drug direct-to-consumer (DTC) promotion expenditure on the Internet experienced triple-digit growth between 2005 and 2009, compared with a decrease in other media channels \[[@ref4]\]. One report \[[@ref5]\] estimated that 3 billion to 7 billion pharmaceutical and drug promotional messages were being delivered online each month. Another noted that US health care and pharmaceutical advertisers spent US \$373 million on mobile formats in 2014 \[[@ref6]\]. Nevertheless, prescription drug promotion, while well represented on the Internet in the form of websites, has been slower to branch into mobile promotion beyond paid searches. One possible cause of this could be the issuance of US Food and Drug Administration (FDA) "enforcement" warning and untitled letters about sponsored links on Internet search engines in 2009 \[[@ref7]\], which stated that online promotion is subject to existing laws and implementing regulations \[[@ref8],[@ref9]\]. In particular, the US Food, Drug, and Cosmetic Act and implementing regulations state that any prescription drug promotion that presents drug benefits to consumers must also disclose certain information about the drug's risks in a similar manner. This concept of "fair balance" may be challenging in mobile promotional communications (hereafter referred to as "mobile communications"), where there are often limitations on the amount of information that can be presented.

Content analyses have found fair balance lacking in DTC marketing in print \[[@ref10]-[@ref12]\], television \[[@ref11],[@ref13]-[@ref15]\], websites \[[@ref16]-[@ref18]\], social media sites \[[@ref19]\], and Internet banners \[[@ref20]\]. It is also important to have an accurate picture of the mobile promotion landscape in order to make informed decisions about mobile DTC promotion. The purpose of this content analysis was to explore the presentation of drug benefits and risks in (1) mobile communications and (2) landing pages (ie, the first page of the website to which the communication linked).

Methods
=======

After evaluating the capabilities of several companies, we chose to use a commercially available dataset of mobile-enhanced DTC promotional communications from Competitrack (Market Track, LLC, Chicago, IL, USA). Competitrack monitors 100 leading apps and mobile-optimized websites, including mobile devices---specifically, iPhones, Android phones, iPads, and Android tablets---by sampling hundreds of top-rated apps and websites to identify those that carry the most distinctive and requested consumer advertising. This media universe is reviewed on a regular basis to identify emerging apps and websites with relevant advertising. Competitrack's database includes information about the type of device used to find the ad, jpg files of the ads, ad landing pages, URLs (if available), and general information (eg, site or app where the ad was found, and type \[news, weather, shopping, health\], date, and brand). We used Competitrack's database to download general information about prescription drug communications, static images of the full communication, and images of the landing pages (jpg files). Although a few of the mobile communications were interactive, we chose to use a "snapshot in time" approach to capture and code communications and landing pages at 1 point in time to avoid problems of replicability. This method allowed 2 coders to analyze identical ads and landing pages to calculate interrater reliability. We identified 266 mobile communications from May 2012 to May 2014.

We selected eligible mobile communications using the following criteria: (1) the communication and the landing page had to be viewable, (2) only 1 communication per brand could be included, (3) the promoted branded prescription drug had to be regulated by FDA's Center for Drug Evaluation and Research (CDER) \[[@ref21]\], and (4) the communication had to be directed at consumers. We excluded 178 duplicates, plus 22 that were not prescription products regulated by CDER, and 9 due to landing page or mobile screenshot viewing issues. We excluded an additional 6 communications during coding: 4 targeted health care providers rather than consumers, 1 had no mobile communication included, and 1 had no landing page. This resulted in a sample of 51 mobile communications ([Table 1](#table1){ref-type="table"}).

###### 

Sample characteristics of mobile communications promoting prescription drugs (N=51).

  Drug name      Source                          Source type   Device           Year
  -------------- ------------------------------- ------------- ---------------- ------
  Abilify        CBS News                        App           iPhone           2013
  Androgel       CNN                             Website       iPad             2013
  Axiron         Fox News                        Website       iPad             2012
  Botox          WeatherBug                      App           iPhone           2013
  Bydureon       AroundMe                        App           Android Phone    2014
  Celebrex       Fox News                        App           iPhone           2013
  Chantix        About.com                       Website       iPad             2013
  Cialis         WeatherBug                      Website       Android Phone    2012
  Complera       CNBC                            Website       Android Phone    2013
  Copaxone       eHow                            Website       iPhone           2014
  Cymbalta       CNN                             Website       Android Phone    2013
  Dexilant       Dictionary.com                  App           Android Phone    2013
  Diclegis       TheStreet                       App           Android Phone    2013
  Dulera         Weatherbug                      Website       Android Phone    2012
  Eliquis        Fox News                        Website       iPad             2013
  EpiPen         eHow                            Website       iPhone           2013
  Evista         Weather.com                     Website       iPad             2013
  Finacea        About.com                       Website       iPad             2014
  Gilenya        MSNBC                           Website       iPad             2013
  Horizant       About.com                       Website       iPad             2013
  Incivek        About.com                       Website       Android Phone    2012
  Intermezzo     New York Times                  Website       iPad             2013
  Intuniv        Learn Spanish Vocabulary Lite   App           Android Phone    2013
  Isentress      About.com                       Website       iPad             2013
  Januvia        WeatherBug                      Website       iPad             2013
  Latuda         CareerBuilder.com               Website       iPad             2014
  Lovaza         Fox News                        Website       iPhone           2013
  Lunesta        WeatherBug                      App           Android Tablet   2013
  Mirena         Fox Sports                      Website       iPad             2013
  Myrbetriq      eHow                            Website       Android Phone    2013
  Nasonex        AccuWeather                     App           iPad             2012
  Nexplanon      Craigslist Mobile               App           Android Phone    2013
  NuvaRing       WeatherBug                      App           iPhone           2012
  Nuvigil        Fox Sports                      Website       iPad             2013
  ParaGard IUD   Dailymotion                     Website       Android Phone    2012
  PlanB          TweetCaster                     App           Android Phone    2012
  Staxyn         Fox News                        Website       iPad             2013
  Stelara        The Weather Channel             App           iPhone           2013
  Strattera      Expedia                         Website       iPhone           2013
  Stribild       About.com                       Website       iPad             2013
  Suboxone       Fox News                        App           iPhone           2013
  Symbicort      Weather.com                     Website       iPhone           2013
  Synthroid      About.com                       Website       iPad             2013
  Tamiflu        CBS Local YourDay               App           iPhone           2012
  Velcade        New York Times                  Website       iPhone           2013
  Vesicare       eHow                            Website       iPhone           2013
  Viagra         NFL.com                         Website       iPad             2013
  Vyvanse        Craigslist Mobile               App           Android Phone    2013
  Xarelto        AOL                             Website       iPad             2013
  Xeljanz        CNN                             Website       iPad             2013
  Zetonna        AccuWeather                     App           iPad             2013

Two raters independently double coded 10% of the sample (5 mobile communications and their related landing pages) to refine the coding scheme, and double coded an additional 10% of the sample to determine interrater reliability (κ=.92 for mobile communication codes and κ=.83 for landing page codes). Disagreements were resolved through discussion. We coded the type of mobile communications and landing pages, the prominence and placement of benefit and risk information, and the presence of links. The type and amount of risk and benefit information in each communication was determined by examining the FDA-approved product labeling for that product. We coded the part(s) of the landing page that were viewable on the screenshot (see [Multimedia Appendix 1](#app1){ref-type="supplementary-material"} for examples). In cases where partial information was visible and ended mid sentence or a capture included additional information that could be accessed through scrolling, as indicated by the presence of a scroll bar, we made the reasonable assumption that it continued below the available screenshot.

Results
=======

Mobile Communication Content and Format
---------------------------------------

Of the 51 mobile communications we coded, 41% (21/51) were product claim communications, 22% (11/51) were reminder communications, and 37% (19/51) were help-seeking communications (see [Multimedia Appendix 2](#app2){ref-type="supplementary-material"} for examples). Scrolling was needed to see all the benefit information on 24% (5/21) of the product claim mobile communications. In contrast, scrolling was needed to see all the risk information on all but 1 of the product claim mobile communications (20/21, 95%). Of the 21 communications, 2 (10%) had additional benefit information available with a link or tab, and 1 (1/21, 5%) had additional risk information available with a link or tab. Of the 19 product claim communications that presented both benefits and risks, 95% (18/19) presented benefits before risks, 47% (9/19) used a bigger font for benefits than for risks, 16% (3/19) used a bigger font size for risks, and 37% (7/19) used the same size font for both.

Of the 51 mobile communications, 37 (72%) included links or tabs to access additional information. The most common link or tab we coded was to the FDA-approved prescribing information \[[@ref22]\] ([Tables 2](#table2){ref-type="table"} and [3](#table3){ref-type="table"}).

Landing Page Content and Format
-------------------------------

The majority of the mobile communications (35/51, 69%) linked to product claim websites, 25% (13/51) linked to landing pages with the drug name and benefit information without visible risk information, and 6% (3/51) linked to landing pages with the drug name and risk information without visible benefit information. Some help-seeking and reminder communications linked to landing pages with the drug name and benefit information without visible risk information ([Table 4](#table4){ref-type="table"}).

###### 

Types of links and tabs (N=51).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of link or tab       Definition                                                                                                                                                                                                                                                                                                                             Mobile promotional communication,\   Landing page,\
                                                                                                                                                                                                                                                                                                                                                                   % (n)                                % (n)
  ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ----------------
  Prescribing information   A compilation of information about the product, written for the health care practitioner audience, approved by the FDA^a^, based on the agency's thorough analysis of the new drug application or biologics license application submitted by the applicant. This labeling contains information necessary for safe and effective use.   37 (19)                              82 (42)

  MedGuide                  FDA-approved information that comes with some prescription medicines, determined to pose a serious and significant public health concern. The MedGuide is designed to help patients avoid serious adverse events. MedGuides are a specific category of Patient Labeling.                                                               22 (11)                              53 (27)

  FDA website               www.fda.gov or www.fda.gov/medwatch                                                                                                                                                                                                                                                                                                    14 (7)                               16 (8)

  Patient information       Labeled as information for patients, patient information, or patient package insert.                                                                                                                                                                                                                                                   6 (3)                                29 (15)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^FDA: US Food and Drug Administration.

###### 

Types of links and tabs by type of mobile promotional communication.

  Type of link or tab       Type of communication, % (n)            
  ------------------------- ------------------------------ -------- -------
  Prescribing information   81 (17)                        18 (2)   0 (0)
  MedGuide                  52 (11)                        0 (0)    0 (0)
  FDA website               33 (7)                         0 (0)    0 (0)
  Patient information       14 (3)                         0 (0)    0 (0)

###### 

Type of mobile promotional communication by type of landing page (N=51).

  Type of communication   Type of landing page, % (n)   Total             
  ----------------------- ----------------------------- --------- ------- ----------
  Product claim           29 (15)                       12 (6)    0 (0)   41 (21)
  Reminder                14 (7)                        6 (3)     2 (1)   22 (11)
  Help seeking            25 (13)                       8 (4)     4 (2)   37 (19)
  Total                   69 (35)                       25 (13)   6 (3)   100 (51)

Nearly all (48/51, 94%) of the landing pages had visible benefit information, and 88% (45/51) had additional benefit information available with a link or tab. Approximately three-quarters of landing pages had visible risk information (38/51, 74%) and 86% (44/51) had additional risk information available with a link or tab. Scrolling was needed to see all the benefit information on 8% (4/51) of the landing pages. In contrast, scrolling was needed to see all the risk information on 51% (26/51) of the landing pages.

Of the 35 landing pages with both benefit and risk information, 71% (25/35) presented benefits before risks, 51% (18/35) used a bigger font for benefits than for risks, 3% (1/35) used a bigger font size for risks, and 46% (16/35) used the same size font for both.

Nearly all the landing pages (48/51, 94%) included links or tabs to access additional information. The most common link or tab we coded was to the FDA-approved prescribing information ([Table 2](#table2){ref-type="table"}).

Discussion
==========

DTC marketing can affect important public health outcomes \[[@ref23]-[@ref25]\], and mobile DTC promotion continues to increase exponentially \[[@ref26]\]. Therefore, it is important to understand the content of this promotion. Surprisingly, 22% of mobile communications were reminder communications, a higher proportion than expected given the scarcity of reminders overall. An informal survey of DTC television ads reveals almost no reminder ads in that medium, which may be a direct result of the Pharmaceutical Research and Manufacturers of America DTC guidelines that encourage DTC ads that name a product to also include both risk and indication information \[[@ref27]\]. Reminder communications may be suited to the mobile space because they do not have to accommodate benefit and risk information. Enforcement in other space-limited Internet venues likely also affected the types of mobile communications used \[[@ref28]\]. Despite FDA guidance in this area \[[@ref9]\], sponsors who remain unsure about how to implement a fairly balanced product claim promotion in this medium may opt instead to use a reminder communication to link to the drug's promotional website \[[@ref29]\].

When mobile communications included both benefits and risks, benefits appeared to be more prominent and easily accessible than risks, although we did not test for significant differences. This echoes prior research across a broad range of marketing platforms and raises concerns about whether fair balance requirements are being met in the mobile marketing of prescription drugs in the United States. Similarly, and consistent with past research, benefits also appeared to be more prominent than risks on landing pages \[[@ref18],[@ref20]\]. It may be that the apparent difference in scrolling needed is because there is often more information in the risk section of approved labeling than in the indication section. Regardless, if risk information is available only through scrolling or a link, consumers may be less likely to access it and may miss important information \[[@ref30]\]. Sponsors should ensure that benefit and risk information in mobile communications and on landing pages is equally prominent and accessible to address fair balance.

Some help-seeking and reminder communications linked to a website with the drug name and benefit information but without visible risk information. The FDA has expressed concerns about linking a drug to an indication without accompanying risk information \[[@ref31]\]. Moreover, research has shown that consumers confuse disease information with branded prescription drug information when the two are presented together \[[@ref32]\] or associated by link \[[@ref33]\]. Situations where reminder or help-seeking communications are linked to full product claim websites may require extra care to ensure the information is truthful, balanced, and nonmisleading.

Limitations
-----------

First, the dataset we used consisted mostly of static screenshots. Thus, we could not code interactive features or information that could be viewed only by scrolling. If the screenshot consisted only of the "above the fold" section of a landing page, we could not determine whether risks or benefits were presented "below the fold." Second, content analysis allows for in-depth analysis of information, but it cannot provide information on how often consumers view mobile communications, what information they understand, or how often they view the landing page. Third, Competitrack did not have an established protocol regarding the orientation of the device. This was done at the discretion of the capture person, but some apps presented the page in landscape by default. As a result, there could potentially be differences in what was captured in a screenshot depending on the device.

Conclusions
-----------

Consumers are increasingly going online for health information, and as digital marketing for prescription drugs is increasing, consumers are more likely to encounter these mobile communications. At the same time, lack of fair balance generally, and minimization of risk information in particular, continue to be frequently cited in FDA letters \[[@ref34]\]. Our findings suggest that sponsors continue to struggle with these issues across promotional platforms. Recent FDA guidance on character space-limited platforms \[[@ref8],[@ref9]\] may help sponsors navigate these issues. The results of this analysis, particularly with respect to the persistent lack of fair balance, may provide useful information to regulators as they consider the available data applicable to policy. Additionally, continued surveillance of DTC marketing online and in mobile communications is needed to ensure that consumers have access to fairly balanced, accurate, and nonmisleading information about medical products.
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